Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
PALOMA-3 update, including OS data for HR positive HER2 negative breast cancer

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.10.18
Views: 1028

Prof Massimo Cristofanilli - Feinberg School of Medicine, Chicago, USA

Prof Massimo Cristofanilli speaks with ecancer at ESMO 2018 in Munich about the analysis of data from the PALOMA-3 study of palbociclib with fulvestrant to treat HR /HER2- breast cancer, following the previous publication of PFS data.

He outlines the importance of prior sensitisation with endocrine therapy in this population, and recommends the combination as a new standard of care.

For more on this trial, watch his presentation of data at a conference session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation